Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAF < sup > V600E < /sup > -Mutated Anaplastic Thyroid Carcinoma

Conclusions: Our results show that in BRAFm-ATC, addition of pembrolizumab to dabrafenib/trametinib may significantly prolong survival. Surgical resection of the primary tumor after initial BRAF-targeted therapy in selected patients may provide further survival benefit. However, conclusions are limited by the retrospective nature of the study. Additional prospective data are needed to confirm this observation.PMID:38226606 | DOI:10.1089/thy.2023.0573
Source: Thyroid : official journal of the American Thyroid Association - Category: Endocrinology Authors: Source Type: research